Skip to main content
. 2020 Apr 1;59(7):901–907. doi: 10.2169/internalmedicine.3382-19

Figure 3.

Figure 3.

Subgroup analyses of the influence of IFN-free DAA therapy on recurrence after curative treatment. Subgroup analyses of the hazard ratio of the influence of IFN-free DAA therapy on HCC recurrence by a time-dependent extended Cox proportional hazards model. HCC: hepatocellular carcinoma, IFN-free DAA: interferon-free direct-acting antiviral therapy